New Key Statistics Module, Z-Score and F-Score
NAS:ENTA Key Ratios
| Market Cap $ M | 273.55 |
| Enterprise Value $ M | -41.71 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.65 |
| Price/Sales | 3.80 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 72.00 |
| EPS (TTM) $ | -6.24 |
| Beneish M-Score | -3.79 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 0.32 |
| EV-to-EBITDA | 0.33 |
| PEG | -- |
| Shares Outstanding M | 21.16 |
| Net Margin (%) | -180.76 |
| Operating Margin % | -185.78 |
| Pre-tax Margin (%) | -178.25 |
| Quick Ratio | 6.43 |
| Current Ratio | 6.43 |
| ROA % (ttm) | -30.98 |
| ROE % (ttm) | -60.88 |
| ROIC % (ttm) | -157.03 |
| Dividend Yield % | -- |
| Altman Z-Score | 0.01 |
ENTA Number of Guru Trades
ENTA Volume of Guru Trades
Gurus Latest Trades with NAS:ENTA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ENTA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Enanta Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:ENTA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers